Artelo Biosciences, Inc. has entered into a Securities Purchase Agreement with Labrys Fund II, L.P., issuing a 10% promissory note totaling $315,000, which includes an original issue discount of $15,000. The net proceeds of $300,000 will be utilized for business development and general working capital. The note matures in 12 months, with provisions allowing for prepayment within the first 181 days. Additionally, the agreement allows Labrys to convert the note into shares of common stock at a conversion price set at 75% of the average of the two lowest closing bid prices during a specified trading period. This financing is expected to bolster Artelo's operational capabilities and support its strategic initiatives, particularly in the development of ART27.13, a potential therapy for muscle preservation in patients undergoing GLP-1 treatments. The company has also announced a strategic expansion opportunity for ART27.13, which is supported by recent positive developments in clinical trials and independent research. This financing and the associated developments are anticipated to have a noticeable positive impact on Artelo's stock price as it positions the company for growth in a rapidly expanding market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.